Jin Xing Qi
Chairman bei HANGZHOU BINJIANG REAL ESTATE GROUP CO.,LTD
Vermögen: 1 642 Mio $ am 31.03.2024
Profil
Jin Xing Qi gründete Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Zurzeit ist er Vorsitzender der Hangzhou Binjiang Real Estate Group Co., Ltd. und Vorsitzender der Hangzhou Pute Equity Investment Co. Ltd. Herr Qi ist außerdem im Vorstand der Hangzhou Binjiang Investment Holding Co., Ltd. und der Hangzhou Xincheng Time Square Real Estate Co., Ltd. sowie Vizepräsident von Zhejiang Management Research. In der Vergangenheit hatte Herr Qi die Position des Direktors bei Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Jin Xing Qi erhielt einen MBA von der Zhejiang Universität.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.09.2023 | 1 505 912 522 ( 55,93% ) | 1 386 Mio $ | 31.03.2024 | |
| 30.09.2023 | 278 698 950 ( 64,95% ) | 256 Mio $ | 31.03.2024 |
Aktive Positionen von Jin Xing Qi
| Unternehmen | Position | Beginn |
|---|---|---|
| HANGZHOU BINJIANG REAL ESTATE GROUP CO.,LTD | Chairman | 01.01.2003 |
| Zhejiang Management Research | Corporate Officer/Principal | 24.02.2010 |
| Hangzhou Pute Equity Investment Co. Ltd. | Chairman | 07.04.2011 |
Hangzhou Binjiang Investment Holding Co., Ltd.
 Hangzhou Binjiang Investment Holding Co., Ltd. MiscellaneousMiscellaneous Hangzhou Binjiang Investment Holding Co., Ltd. is an investment holding private company based in Hangzhou, China. | Director/Board Member | - |
Hangzhou Xincheng Time Square Real Estate Co., Ltd.
 Hangzhou Xincheng Time Square Real Estate Co., Ltd. Real Estate DevelopmentFinance Part of Hangzhou Binjiang Real Estate Group Co., Ltd., Hangzhou Xincheng Time Square Real Estate Co., Ltd. develops and manages real estate property. The private company is based in Hangzhou, China. | Director/Board Member | - |
Ehemalige bekannte Positionen von Jin Xing Qi
| Unternehmen | Position | Ende |
|---|---|---|
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
 Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Founder | - |
Ausbildung von Jin Xing Qi
| Zhejiang University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HANGZHOU BINJIANG REAL ESTATE GROUP CO.,LTD | Finance |
| Private Unternehmen | 5 |
|---|---|
Hangzhou Binjiang Investment Holding Co., Ltd.
Hangzhou Binjiang Investment Holding Co., Ltd. MiscellaneousMiscellaneous Hangzhou Binjiang Investment Holding Co., Ltd. is an investment holding private company based in Hangzhou, China. | Miscellaneous |
| Zhejiang Management Research | |
Hangzhou Xincheng Time Square Real Estate Co., Ltd.
Hangzhou Xincheng Time Square Real Estate Co., Ltd. Real Estate DevelopmentFinance Part of Hangzhou Binjiang Real Estate Group Co., Ltd., Hangzhou Xincheng Time Square Real Estate Co., Ltd. develops and manages real estate property. The private company is based in Hangzhou, China. | Finance |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Health Technology |
| Hangzhou Pute Equity Investment Co. Ltd. | Finance |
